Contraception for Specific Populations

CEU Statement: Sodium Valproate and Pregnancy Risks (February 2016)

01 February 2016

The Medicines and Healthcare products Regulatory Agency (MHRA) recently launched a toolkit for healthcare professionals (HCPs) regarding sodium valproate in order to communicate its teratogenic effects. The CEU recommends that all HCPs be prepared to provide information about and access to effective contraception for women who have undergone treatment with valproate-related medicines.

This document is up-to-date

CEU Statement: Management of women taking anticoagulants or antiplatelet medications who request intrauterine contraception or subdermal implants - March 2017

29 March 2017

This statement aims to encourage the consistent and safe management of women requesting intrauterine contraception (IUC) and subdermal implants (SDI) who are taking anticoagulants or antiplatelet medications. It is primarily aimed at clinicians working in primary care and community sexual and reproductive health clinics.

This document is up-to-date